Biomira Inc. announced Tuesday that it has granted a non-exclusive license to its antibody B27.29 to Behringwerke A.G., awholly owned subsidiary of Hoechst A.G. The B27.29 antibodyis used in Behringwerke's Berilux semi-automated analyzer, abreast tumor marker hybrid assay.

Behringwerke of Marburg, Germany, has been developing theBerilux assay since late 1992, according to Biomira, and expectsto launch the product in Europe this summer.

Biomira of Edmonton, Alberta, licensed its B43.13/B27.1antibody to Behringwerke in late 1991, the company said. Thatantibody is used in an ovarian cancer tumor marker assay.

Biomira will receive an undisclosed initial licensing fee plusroyalties on the future sale of any Behringwerke productscontaining the B27.29 antibody. BioMira (NASDAQ:BIOMF) willsupply the company with the antibody and antigen. -- KarlThiel

(c) 1997 American Health Consultants. All rights reserved.